Changes in heart transplantation (HT) donor and recipient demographics may influence the incidence of primary graft dysfunction (PGD). We conducted a retrospective study to evaluate PGD incidence, trends, and associated risk factors by analyzing consecutive adult patients who underwent HT between January 2009 and December 2014 at our institution. Patients were categorized as having PGD using the International Society for Heart & Lung Transplantation (ISHLT)-defined criteria.
PGD is common and ranges from 2.3% to 28.2% depending on the definition used. [6] [7] [8] [9] [10] The etiology of PGD is likely multifactorial due to both donor-and recipient-related factors. Donor hearts are at risk of ischemia/reperfusion injury, damage from proinflammatory cytokines, and decreased donor cortisol and thyroid hormone levels. [11] [12] [13] [14] [15] Recipient-related factors include age, increased pulmonary vascular resistance (PVR), and recipient inflammatory cytokines, which can worsen vasoplegia as well as oxidative stress in the transplanted heart. 6, 10, [16] [17] [18] [19] In addition, transplant recipient dependence on pretransplantation inotropic support and mechanical ventilation have been associated with increased incidence of PGD. 8, [20] [21] [22] Both the left ventricle (LV) and right ventricle (RV) are at risk for PGD. In a single-center study, Segovia et al developed a predictive model for the development of PGD. The risk factors included in the model and used to calculate a predictive score are recipient age ≥60 years, recipient diabetes mellitus, recipient inotrope dependence, right atrial pressure ≥10 mm Hg, donor age ≥30 years, and ischemic time ≥4 hours (RADIAL score). 10 This model was later validated in a separate cohort of HT performed at programs in Spain between 2006 and 2010. 23 In the latter study, PGD occurred with an incidence of 22%. Isolated RV dysfunction was present in 45% of patients with PGD, whereas isolated LV PGD occurred in 8% of PGD patients and combined biventricular PGD in 47% of patients. The RADIAL score was higher in patients with PGD and stratified patients into groups with incremental PGD incidence. 23 The widespread adoption of pretransplantation mechanical circulatory support technology and increase in utilization of hearts from older donors may have changed the demographics of both recipients as well as donors in the current era of cardiac transplantation. We therefore conducted a single-center retrospective cohort study to evaluate the incidence, trends, and independently associated risk factors for PGD after HT. In addition, we explored the performance of the RADIAL score variables in our study population. (Table S1 ). The data listed in the UNOS (500 mL) was administered to the heart via the aortic root after completion of the left atrial anastomosis. Following this, the aortic anastomosis was completed, the aortic cross-clamp was removed, and the transplanted heart was reperfused. Thirty minutes of filtration was performed through a leukocyte depletion filter prior to heart reperfusion. Anesthesia and cardiopulmonary bypass (CPB) were conducted according to institutional protocol.
| MATERIALS AND METHODS

| Patient population
Intraoperative hemodynamic assessment was performed in all patients using a pulmonary artery catheter, and right atrial, right ventricular, and pulmonary artery pressures and cardiac index were recorded.
Posttransplantation comprehensive intraoperative transesophageal echocardiography (TEE) was performed for all patients according to published guidelines. Inotrope score was calculated using the formula recommended by the ISHLT consensus statement: inotrope score = dopamine (x1) + dobutamine (x1) + milrinone (x15) + epinephrine (x100) + norepinephrine (x100) with each drug dosed in mcg/kg/min. and no-PGD groups via cumulative incidence functions using Gray's competing risks methods. [28] [29] [30] When analyzing in-hospital mortality, discharge was considered the competing event, and for the LOS analysis, in-hospital mortalities were the competing event. Patient followup was truncated at 100 days and if patients neither died in-hospital nor was discharged by 100 days they were censored in both analyses.
Baseline characteristics were screened for association with PGD.
Variables associated at the nominal P ≤ .20 significance level in the univariable analysis were considered in a stepwise selection for a multivariable logistic regression model to assess the independent association and statistical significance of each variable. Variables associated with PGD at a P ≤ .05 level of significance were retained in the final model.
Because PGD not requiring VAD placement may be considered a less severe form of PGD, we performed a sensitivity analysis using the final multivariable logistic regression model, but excluded patients who met PGD criteria without a VAD placed to ensure that the identified factors remained associated. We conducted a second sensitivity analysis in which we created a 3-level ordinal outcome (no-PGD, PGD without VAD, and PGD with VAD) and used a multivariable proportional odds model to evaluate whether the identified risk factors were associated with severity of PGD. The score test was used to evaluate the proportionality assumption, and C-index was used to evaluate model performance.
To investigate potential time-trends in either PGD incidence or donor and recipient characteristics over the study period we used the Cochrane-Armitage trend test for categorical variables and Spearman correlation for the numeric variables. We also investigated performance of the RADIAL score in our cohort via chi-square test and
Cochran-Armitage trend test for ordinal score. The RADIAL score was calculated by adding one point for each of the following 6 variables present: recipient age ≥60 years, recipient diabetes mellitus, recipient inotrope dependence, right atrial pressure ≥10 mm Hg, donor age ≥30 years, and ischemic time ≥4 hours. 10 We investigated the association of both the raw RADIAL score and the 4-level category score proposed by Segovia et al.
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| RESULTS
A total of 325 adult patients underwent HT during the study period. Table 1 . In the univariable analysis we identified 3 significant differences between the PGD outcome groups; patients who developed PGD versus no PGD had a longer median donor ischemic time (3.2 vs 2.8 hours, P < .01), were more frequently of African American race (36.4% vs 24.3% P = .03), and had a higher right atrial pressure (RAP) on the pretransplantation evaluation right heart catheterization (12 vs 9.5 mm Hg, P = .04). There was no difference between the study groups in the percentage of patients sensitized with class 1 or class 2
anti-HLA antibodies or in the mismatch level for antigens A, B, and DR.
There was no difference in the number of patients with positive flow cytometry with crossmatch T cells and/or B cells (Table 2) .
Eleven in-hospital deaths (3.5%) occurred in our study cohort.
The in-hospital mortality rate was significantly higher among patients with PGD versus those without (10.1% vs 0.5%, OR 24.38, 95% CI group. There were also significantly increasing trends for in-hospital, 30-day, and 1-year mortality as severity of PGD increased (Table 3 ).
Median hospital LOS for patients who survived was 17 days (IQR 11, 31) for patients with PGD compared to 10 days (IQR 8, 15) for patients without PGD (Table 3 ). The Gray's test of the cause-specific cumulative hazard function for posttransplantation LOS indicated patients with PGD had significantly increased posttransplantation LOS compared to patients without PGD (P < .001).
There were 11 variables from the univariable analysis that were considered in stepwise model building for inclusion in the final multivariable model (details in Table S2 ). The final multivariable model We also found that African American patients were more likely to be HLA sensitized when compared with other races for both class 1 (46.1% vs 32.9%, P = .03) and class 2 antigens (24.7% vs 13.7%, P = .02); however, the most recent panel reactive antibody (PRA) activity for those with positive antibodies was not significantly different between African American recipients and other races for both class 1 (10 vs 13, P = .96) and class 2 antigens (15.5 vs 15.0, P = .49). African
American recipients were also more likely to have an LVAD pretransplantation (44.9% vs 28.2%, P = .004) compared with other races.
In the time-trend analysis, we found that the incidence of PGD did not change over the study period (01/2009 to 12/2014). Of the variables independently associated with PGD, recipient pretransplantation treatment with amiodarone significantly increased over time (P < .01).
Other variables we studied that have significantly increased over the study period are recipient pretransplantation durable LVAD (P < .01), Represents number and percentage, n (%), of population with antibodies present to class 1 or class 2 HLA antigens in each of the 3 study groups.
No PGD (N = 218) PGD (N = 99) Total (N = 317) P-value
T A B L E 2 Sensitization and HLAmatching level between outcome groups the time from declaration of donor brain death and placement of the aortic cross-clamp during organ harvest (P < .01), and donor diagnosis of pulmonary infection (P < .0001). Recipient-donor gender mismatch decreased over the study period (P < .01). Graphic representation of some of these trends is presented in Figure 3 .
We calculated the RADIAL score in our cohort and the most frequent RADIAL scores in the study cohort were 2 (66 patients) and 3
(65 patients). There was no difference in the incidence of PGD with increasing RADIAL score (P = .85) ( Table 4 ).
| DISCUSSION
Of the 317 patients who underwent HT at our center over the study period and met inclusion criteria, 99 (31.23%) developed PGD defined according to the ISHLT consensus statement. Isolated PGD-LV occurred in 60 patients (18.9%), 22 patients (7%) had biventricular PGD, and 17 patients (5.3%) had isolated PGD-RV. Risk factors independently associated with type of PGD included ischemia time, recipient African American race, and recipient pretransplantation treatment with amiodarone. In-hospital, 30-day, and 1-year mortality were significantly increased in patients who developed PGD compared with patients without PGD. Several variables changed over the study period at our institution, including an increase in the recipient pretransplantation treatment with amiodarone. The incidence of PGD did not change significantly over the study period at our institution.
An international survey of 47 heart transplant centers, preceding the 2013 consensus conference on PGD of the ISHLT, comprising almost 10 000 patients, found that PGD occurred at a rate of 7.4%.
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Other single-center studies have reported incidences ranging from 2.5% to 24% depending on the stringency of the PGD definition. 6, 23, 31 Two recent studies investigated the incidence of PGD using the ISHLT consensus statement criteria and found an incidence of 13.9% and 30%. 32, 33 We chose not to use hemodynamic variables such as cardiac Intriguingly, we found recipient African American race also to be associated with a 1.8 times higher odds of developing biventricular PGD. This has been described in PGD development after lung transplantation. 35 The underlying mechanism for this observation may reflect differences in vascular endothelium, 35 or potentially a more robust inflammatory response surrounding the postoperative period, although these explanations are highly speculative. HLA mismatch has been shown to be associated with unfavorable outcomes in kidney, liver, and heart transplantation, 36-38 so it is likely that sensitization plays a role in the pathogenesis of graft dysfunction. 39 In a recent meta-analysis, Morris et al found that African American patients were more likely to be sensitized, have a higher peak PRA value, and were more likely to experience graft failure compared to Hispanic, white, or Asian recipients.
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In our study cohort, we also found that African American patients were more likely to be HLA sensitized compared with other races for both CI, confidence interval; OR, odds ratio; PGD, primary graft dysfunction F I G U R E 3 Trend over time for PGD incidence, for variables independently associated with PGD and for other variables that showed significant change over the study period. The graphs display either median and interquartile range (Q1, Q3) or percent and confidence interval (CI). LVAD, left ventricular assist device; PGD, primary graft dysfunction; Tx, transplant transplantation 40 and in heart transplantation, 41 we did not find any of these variables to be significantly different in our study. However, we did find a significant decrease in the recipient-donor gender mismatch over the study period (P = .0034, Figure 2 ), possibly reflecting a change in selection over time.
Amiodarone treatment of the recipient pretransplantation has been controversially discussed, with divergent results regarding early graft failure, morbidity, and mortality after heart transplantation. [42] [43] [44] We have found recipient pretransplantation use of amiodarone as an independent risk factor for PGD development, the use of amiodarone increasing the risk of PGD by 67%. The thirty-second official adult heart transplantation report from the registry of ISHLT did not find amiodarone independently associated with early graft failure, but we had a higher frequency of early graft failure and inhospital graft dysfunction among patients treated with amiodarone, suggesting that amiodarone may play a role in early posttransplantation outcomes or may be associated with unmeasured confounders indicating a more ill patient population. 45 A recent retrospective cohort analysis of adult HT recipients from the ISHLT registry found that amiodarone use before HT has increased over time and is associated with increased 1-year mortality. 46 We have also observed an increase in the use of amiodarone pretransplantation over the study period at our institution. The long half-life of amiodarone combined with its pharmacological effects (negative chronotropic and inotropic, calcium channel blockage, and α-and β-receptor blockade) may be responsible for its effects or an unidentified interaction with oxidative stress leading to worsening ischemia-reperfusion injury, but this is speculative.
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Donor brain death is associated with pathophysiological changes that could result in impaired myocardial contractility such as rapid release of catecholamines and activation of multiple proinflammatory mediators. 11, 47 Intuitively, cardiac function can deteriorate rapidly in the time period from brain death to heart retrieval. Although we noticed a significant increase in the time period from declaration of brain death to aortic cross-clamp placement for donor organ harvest (P = .0048, Figure 2) , there was no difference in the duration of this time interval between patients who did and did not develop PGD. In addition, decreased levels of various hormones (triiodothyronine, cortisol, insulin) may contribute to myocardial dysfunction in the donor after brain death. 48, 49 We did not find a difference between groups regarding the pre-heart retrieval treatment of the donor with thyroid hormone or corticosteroids (Table 1) . We did not find a difference in donor age or donor-recipient BMI percent difference between the PGD and no-PGD groups. We also did not find an increase in donor age across the study period. Similar to Segovia et al, 10 we found a significant difference in the preoperative RAP between patients who did and did not develop PGD, probably as a reflection of preoperative RV failure and long-standing pulmonary hypertension. There was no difference between the two groups in the preoperative pulmonary systolic and diastolic pressure; however, these parameters can be underestimated in the presence of RV dysfunction.
The only validated scoring system for the prediction of PGD is the RADIAL score, 10, 23 which was validated in a Spanish cohort of heart transplant recipients. In our study cohort we did not find the RADIAL score to be predictive of PGD. This may be due to the different eras in heart transplantation investigated in the prior studies or the different treatment processes between countries from which the data are obtained. In addition, the development of VAD technology is likely to have changed the profile of the heart transplant recipient in the past decade. While Segovia et al 10 and Carmena et al, 23 found that the percentage of patients bridged to HT with a durable LVAD was 2.5% and 6.7%, respectively, in our study cohort 32.9% of patients had a durable LVAD.
Segovia et al studied historical trends in the incidence of PGD in a single-center study spanning 2 decades and found a trend in increase of incidence for PGD overall. 10 We did not find a change in PGD incidence across the study period, although the PGD incidence was highest in the last 2 years of our study period. Further investigation and data collection is necessary to establish a trend in the data.
We report an in-hospital mortality of 23% for patients with PGD requiring VAD (which would be classified as severe PGD by ISHLT criteria) and 1.7% for patients with PGD without VAD (which would be In conclusion, we found that PGD is common and that longer 
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